Nonresponders and rare mutation classes: ex vivo models to test CFTR modulator efficacy

I. Oglesby (Dublin 9, Ireland)

Source: International Congress 2022 – Long-term impact of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis patients and potential changes in the management of the disease in CF units

Session: Long-term impact of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis patients and potential changes in the management of the disease in CF units
Session type: Mini symposium
Number: 4371

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Oglesby (Dublin 9, Ireland). Nonresponders and rare mutation classes: ex vivo models to test CFTR modulator efficacy. International Congress 2022 – Long-term impact of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis patients and potential changes in the management of the disease in CF units

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.